{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:55:45Z","timestamp":1794012945720,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaut.2023.103125","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:26:25Z","timestamp":1697289985000},"page":"103125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-1410","authenticated-orcid":false,"given":"Takashi Kei","family":"Kishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Nukolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-ni","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"VanDyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Traber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie B.","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon S.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr O.","family":"Ilyinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2023.103125_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.aau2688","article-title":"Treg cells-the next frontier of cell therapy","volume":"362","author":"Bluestone","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaut.2023.103125_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104236","article-title":"Regulating the regulators: is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?","volume":"358","author":"Janssens","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib5","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ajpath.2020.05.007","article-title":"The surprising story of IL-2: from experimental models to clinical application","volume":"190","author":"Abbas","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2023.103125_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2023.103125_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2023.103125_bib10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/protein\/gzg111","article-title":"Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity","volume":"16","author":"Rao","year":"2003","journal-title":"Protein Eng."},{"key":"10.1016\/j.jaut.2023.103125_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells","volume":"56","author":"Bell","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2023.103125_bib14","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3389\/fimmu.2020.01106","article-title":"Defining the Threshold IL-2 signal required for induction of selective Treg cell responses using engineered IL-2 muteins","volume":"11","author":"Ghelani","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaut.2023.103125_bib16","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/s41467-022-31130-9","article-title":"Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein","volume":"13","author":"de Picciotto","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2023.103125_bib17","article-title":"NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases","volume":"4","author":"Dixit","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jaut.2023.103125_bib18","article-title":"Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus","volume":"5","author":"Fanton","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jaut.2023.103125_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","article-title":"Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease","volume":"6","author":"Boyman","year":"2006","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2023.103125_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib21","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.4049\/jimmunol.1800578","article-title":"Engineering a single-Agent cytokine\/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy","volume":"201","author":"Spangler","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111478","article-title":"Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection","volume":"41","author":"VanDyke","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.jaut.2023.103125_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb9283","article-title":"Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species","volume":"12","author":"Karakus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib24","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2337\/db20-0186","article-title":"Persistent IL-2 receptor signaling by IL-2\/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms","volume":"69","author":"Ward","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2023.103125_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104160","article-title":"Regulatory T cells: master thieves of the immune system","volume":"355","author":"Akkaya","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.164.1.183","article-title":"Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific","volume":"164","author":"Thornton","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib27","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/eji.200425887","article-title":"Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango","volume":"35","author":"Scheffold","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2023.103125_bib29","article-title":"Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2023.103125_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.891925","article-title":"Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation","volume":"13","author":"Meguri","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5483\/BMBRep.2019.52.4.271","article-title":"Interleukin-2\/antibody complex expanding Foxp3(\uff0b) regulatory T cells exacerbates Th2-mediated allergic airway inflammation","volume":"52","author":"Hong","year":"2019","journal-title":"BMB Rep"},{"key":"10.1016\/j.jaut.2023.103125_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature22329","article-title":"Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells","volume":"545","author":"Ooi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2023.103125_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41590-018-0280-2","article-title":"Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells","volume":"20","author":"Akkaya","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib34","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib35","doi-asserted-by":"crossref","first-page":"E6192","DOI":"10.1073\/pnas.1611723113","article-title":"Antigen exposure shapes the ratio between antigen-specific Tregs and conventional T cells in human peripheral blood","volume":"113","author":"Su","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2023.103125_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cell.2016.09.050","article-title":"Regulatory T cell specificity Directs tolerance versus Allergy against Aeroantigens in humans","volume":"167","author":"Bacher","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2023.103125_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","article-title":"Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia","volume":"13","author":"Sands","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2023.103125_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a Randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103125_bib39","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2023.103125_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jaut.2023.103125_bib42","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2023.103125_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637469","article-title":"Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles","volume":"12","author":"Ilyinskii","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fimmu.2018.00281","article-title":"Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis","volume":"9","author":"LaMothe","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib45","doi-asserted-by":"crossref","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Pt 1","key":"10.1016\/j.jaut.2023.103125_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/bj2890081","article-title":"Expression and lipoylation in Escherichia coli of the inner lipoyl domain of the E2 component of the human pyruvate dehydrogenase complex","volume":"289","author":"Quinn","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.jaut.2023.103125_bib52","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.20051911","article-title":"NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis","volume":"203","author":"Irie","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib53","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.173.4.2315","article-title":"Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain","volume":"173","author":"Koarada","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib47","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4049\/immunohorizons.2100051","article-title":"In Vivo expansion of antigen-specific regulatory T cells through staggered Fc.IL-2 mutein dosing and antigen-specific immunotherapy","volume":"5","author":"Pham","year":"2021","journal-title":"Immunohorizons"},{"key":"10.1016\/j.jaut.2023.103125_bib48","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.4049\/jimmunol.181.10.7221","article-title":"CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice","volume":"181","author":"Wei","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib49","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2023.103125_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jaut.2023.103125_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MED.0000000000000490","article-title":"Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes","volume":"26","author":"Baker","year":"2019","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.jaut.2023.103125_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2023.103125_bib55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/73200","article-title":"In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope","volume":"6","author":"Anderson","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","article-title":"Immunity to citrullinated proteins in rheumatoid arthritis","volume":"26","author":"Klareskog","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib57","doi-asserted-by":"crossref","first-page":"a007765","DOI":"10.1101\/cshperspect.a007765","article-title":"Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?","volume":"2","author":"Marrack","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jaut.2023.103125_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2016.09.007","article-title":"A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes","volume":"43","author":"Roep","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2023.103125_bib59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2796.2009.02102.x","article-title":"Autoantigens in systemic autoimmunity: critical partner in pathogenesis","volume":"265","author":"Rosen","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib60","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2023.103125_bib61","first-page":"15","article-title":"Immunogenicity of biological therapeutics: a hierarchy of concerns","volume":"112","author":"Rosenberg","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.jaut.2023.103125_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2023.103125_bib63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production","volume":"188","author":"Thornton","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaut.2007.12.012","article-title":"Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells","volume":"30","author":"Long","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2023.103125_bib65","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2023.103125_bib66","doi-asserted-by":"crossref","first-page":"16246","DOI":"10.1073\/pnas.1007422107","article-title":"Enhancement of antigen-specific Treg vaccination in vivo","volume":"107","author":"Daniel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2023.103125_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add8693","article-title":"Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis","volume":"9","author":"Rhodes","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jaut.2023.103125_bib68","article-title":"IL-2 treatment can be dangerous. Here's how drug firms are trying to fix it","volume":"99","author":"Satyanarayana","year":"2021","journal-title":"Chem. Eng. News"},{"key":"10.1016\/j.jaut.2023.103125_bib69","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2023.103125_bib70","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.4049\/jimmunol.171.8.4175","article-title":"Ex vivo analysis of thymic CD4 T Cells in Nonobese Diabetic mice with tetramers generated from I-Ag7class II-associated invariant chain peptide precursors","volume":"171","author":"Jang","year":"2003","journal-title":"J Immunmol"},{"key":"10.1016\/j.jaut.2023.103125_bib71","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1084\/jem.20011353","article-title":"Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice","volume":"196","author":"Gagnerault","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2023.103125_bib72","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, Teplizumab, in relatives at risk for Type 1 Diabetes","volume":"381","author":"Herold etal","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:34:06Z","timestamp":1760258046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841123001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":72,"alternative-id":["S0896841123001348"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103125","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103125"}}